论文部分内容阅读
目的:探讨放疗患者在进行同期化疗的肿瘤患者末端瓣膜式高压注射型经外周静脉置入中心静脉导管时的安全性.方法:将2017年12月至2020年3月作为研究时段,将该时段我院数据库内资料登记有效的肿瘤患者60名作为研究对象,所有患者在接受治疗时均选择化疗方案,在治疗期间患者需留置末端瓣膜式高压注射型经外周静脉置入中心静脉导管;对所有患者进行随机两组均分,单组内设置30名患者,按照实验习惯记录为对照组与实验组.对照组采用耐高压注射型PICC实验组患者应用末端瓣膜式高压注射型经外周静脉置入中心静脉导管.记录两组不良反“,”Objective:To investigate the safety of terminal valvular high-pressure injection of central venous catheter through peripheral vein in tumor patients undergoing concurrent chemotherapy.Methods:the period from December 2017 to March 2020 was taken as the study period,and 60 tumor patients with effective data registered in the database of our hospital during this period were taken as the study objects.All patients chose the chemotherapy scheme when receiving treatment.During the treatment period,patients need to indwelling the terminal valve type high-pressure injection type and place the central venous catheter through the peripheral vein;All patients were randomly divided into two groups.30 patients were set in a single group and recorded as control group and experimental group according to experimental habits.The control group was treated with high-pressure injection type PICC,and the experimental group was treated with terminal valve high-pressure injection type central venous catheter through peripheral vein.The adverse reactions of the two groups were recorded.Results:in the experimental results,two groups of patients had different degrees of adverse reactions,and the incidence rate of the experimental group was significantly lower than that of the control group.The difference between the 0.05 groups was significant(P ＜ 0.05).Conclusion:the selection of terminal valve type high-pressure injection and placement of central venous catheter through peripheral vein can help to reduce the incidence of complications and reduce the workload of nursing staff.